Efficacy and Safety of a Personalized Vitamin D<sub<3</sub< Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial

A personalized vitamin D<sub<3</sub< loading dose has not yet been tested in cancer patients. This interim analysis of the randomized, placebo-controlled VICTORIA trial analyzed the first recruited 74 German adults with nonmetastatic colorectal cancer, a tumor surgery within the past yea...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Sabine Kuznia [verfasserIn] David Czock [verfasserIn] Annette Kopp-Schneider [verfasserIn] Reiner Caspari [verfasserIn] Harald Fischer [verfasserIn] Dana Clarissa Laetsch [verfasserIn] Marija Slavic [verfasserIn] Hermann Brenner [verfasserIn] Ben Schöttker [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2022

Schlagwörter:	vitamin D colorectal cancer randomized controlled trial personalized medicine loading dose bolus

Übergeordnetes Werk:	In: Nutrients - MDPI AG, 2009, 14(2022), 21, p 4546
Übergeordnetes Werk:	volume:14 ; year:2022 ; number:21, p 4546

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/nu14214546

Katalog-ID:	DOAJ086474995

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ086474995
003	DE-627
005	20240414171533.0
007	cr uuu---uuuuu
008	230311s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/nu14214546 \|2 doi
035			\|a (DE-627)DOAJ086474995
035			\|a (DE-599)DOAJ835cb6dd73954dfd9d9fb5a75c27dc3d
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a TX341-641
100	0		\|a Sabine Kuznia \|e verfasserin \|4 aut
245	1	0	\|a Efficacy and Safety of a Personalized Vitamin D<sub<3</sub< Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a A personalized vitamin D<sub<3</sub< loading dose has not yet been tested in cancer patients. This interim analysis of the randomized, placebo-controlled VICTORIA trial analyzed the first recruited 74 German adults with nonmetastatic colorectal cancer, a tumor surgery within the past year, and 25-hydroxyvitamin D levels (25(OH)D) < 50 nmol/L. Study participants received a loading dose tailored for a baseline 25(OH)D level and BMI in the first 11 days, followed by a maintenance dose of 2000 IU of vitamin D<sub<3</sub< daily until end of trial week 12. The mean 25(OH)D levels were 27.6, 31.0, and 34.1 nmol/L in the placebo group and 25.9, 63.1, and 75.5 nmol/L in the verum group during screening, visit 1 (end of loading dose), and visit 2 (end of maintenance dose), respectively. The prevalence of 25(OH)D) ≥ 50 nmol/L at visits 1 and 2 was 3.5% and 17.4% in the placebo group and 80.0% and 100% in the verum group. No events of 25(OH)D < 150 nmol/L or hypercalcemia were observed. Hypercalciuria events at visit 1 (<i<n</i< = 5 in verum and <i<n</i< = 1 in the placebo group; <i<p</i< = 0.209) receded after discontinuation of the study medication. The personalized loading dose effectively and safely increased the 25(OH)D levels, and 2000 IU of vitamin D<sub<3</sub< daily sustained the achieved levels.
650		4	\|a vitamin D
650		4	\|a colorectal cancer
650		4	\|a randomized controlled trial
650		4	\|a personalized medicine
650		4	\|a loading dose
650		4	\|a bolus
653		0	\|a Nutrition. Foods and food supply
700	0		\|a David Czock \|e verfasserin \|4 aut
700	0		\|a Annette Kopp-Schneider \|e verfasserin \|4 aut
700	0		\|a Reiner Caspari \|e verfasserin \|4 aut
700	0		\|a Harald Fischer \|e verfasserin \|4 aut
700	0		\|a Dana Clarissa Laetsch \|e verfasserin \|4 aut
700	0		\|a Marija Slavic \|e verfasserin \|4 aut
700	0		\|a Hermann Brenner \|e verfasserin \|4 aut
700	0		\|a Ben Schöttker \|e verfasserin \|4 aut
773	0	8	\|i In \|t Nutrients \|d MDPI AG, 2009 \|g 14(2022), 21, p 4546 \|w (DE-627)610604155 \|w (DE-600)2518386-2 \|x 20726643 \|7 nnns
773	1	8	\|g volume:14 \|g year:2022 \|g number:21, p 4546
856	4	0	\|u https://doi.org/10.3390/nu14214546 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/835cb6dd73954dfd9d9fb5a75c27dc3d \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/2072-6643/14/21/4546 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2072-6643 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 14 \|j 2022 \|e 21, p 4546

Indexfelder

author_variant	s k sk d c dc a k s aks r c rc h f hf d c l dcl m s ms h b hb b s bs
matchkey_str	article:20726643:2022----::fiaynsftoaesnlzdiaidu3ulaigoeolwdyal20iiclrcacneptetwtvtmnisfiin
hierarchy_sort_str	2022
callnumber-subject-code	TX
publishDate	2022
allfields	10.3390/nu14214546 doi (DE-627)DOAJ086474995 (DE-599)DOAJ835cb6dd73954dfd9d9fb5a75c27dc3d DE-627 ger DE-627 rakwb eng TX341-641 Sabine Kuznia verfasserin aut Efficacy and Safety of a Personalized Vitamin D<sub<3</sub< Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier A personalized vitamin D<sub<3</sub< loading dose has not yet been tested in cancer patients. This interim analysis of the randomized, placebo-controlled VICTORIA trial analyzed the first recruited 74 German adults with nonmetastatic colorectal cancer, a tumor surgery within the past year, and 25-hydroxyvitamin D levels (25(OH)D) < 50 nmol/L. Study participants received a loading dose tailored for a baseline 25(OH)D level and BMI in the first 11 days, followed by a maintenance dose of 2000 IU of vitamin D<sub<3</sub< daily until end of trial week 12. The mean 25(OH)D levels were 27.6, 31.0, and 34.1 nmol/L in the placebo group and 25.9, 63.1, and 75.5 nmol/L in the verum group during screening, visit 1 (end of loading dose), and visit 2 (end of maintenance dose), respectively. The prevalence of 25(OH)D) ≥ 50 nmol/L at visits 1 and 2 was 3.5% and 17.4% in the placebo group and 80.0% and 100% in the verum group. No events of 25(OH)D < 150 nmol/L or hypercalcemia were observed. Hypercalciuria events at visit 1 (<i<n</i< = 5 in verum and <i<n</i< = 1 in the placebo group; <i<p</i< = 0.209) receded after discontinuation of the study medication. The personalized loading dose effectively and safely increased the 25(OH)D levels, and 2000 IU of vitamin D<sub<3</sub< daily sustained the achieved levels. vitamin D colorectal cancer randomized controlled trial personalized medicine loading dose bolus Nutrition. Foods and food supply David Czock verfasserin aut Annette Kopp-Schneider verfasserin aut Reiner Caspari verfasserin aut Harald Fischer verfasserin aut Dana Clarissa Laetsch verfasserin aut Marija Slavic verfasserin aut Hermann Brenner verfasserin aut Ben Schöttker verfasserin aut In Nutrients MDPI AG, 2009 14(2022), 21, p 4546 (DE-627)610604155 (DE-600)2518386-2 20726643 nnns volume:14 year:2022 number:21, p 4546 https://doi.org/10.3390/nu14214546 kostenfrei https://doaj.org/article/835cb6dd73954dfd9d9fb5a75c27dc3d kostenfrei https://www.mdpi.com/2072-6643/14/21/4546 kostenfrei https://doaj.org/toc/2072-6643 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 14 2022 21, p 4546
spelling	10.3390/nu14214546 doi (DE-627)DOAJ086474995 (DE-599)DOAJ835cb6dd73954dfd9d9fb5a75c27dc3d DE-627 ger DE-627 rakwb eng TX341-641 Sabine Kuznia verfasserin aut Efficacy and Safety of a Personalized Vitamin D<sub<3</sub< Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier A personalized vitamin D<sub<3</sub< loading dose has not yet been tested in cancer patients. This interim analysis of the randomized, placebo-controlled VICTORIA trial analyzed the first recruited 74 German adults with nonmetastatic colorectal cancer, a tumor surgery within the past year, and 25-hydroxyvitamin D levels (25(OH)D) < 50 nmol/L. Study participants received a loading dose tailored for a baseline 25(OH)D level and BMI in the first 11 days, followed by a maintenance dose of 2000 IU of vitamin D<sub<3</sub< daily until end of trial week 12. The mean 25(OH)D levels were 27.6, 31.0, and 34.1 nmol/L in the placebo group and 25.9, 63.1, and 75.5 nmol/L in the verum group during screening, visit 1 (end of loading dose), and visit 2 (end of maintenance dose), respectively. The prevalence of 25(OH)D) ≥ 50 nmol/L at visits 1 and 2 was 3.5% and 17.4% in the placebo group and 80.0% and 100% in the verum group. No events of 25(OH)D < 150 nmol/L or hypercalcemia were observed. Hypercalciuria events at visit 1 (<i<n</i< = 5 in verum and <i<n</i< = 1 in the placebo group; <i<p</i< = 0.209) receded after discontinuation of the study medication. The personalized loading dose effectively and safely increased the 25(OH)D levels, and 2000 IU of vitamin D<sub<3</sub< daily sustained the achieved levels. vitamin D colorectal cancer randomized controlled trial personalized medicine loading dose bolus Nutrition. Foods and food supply David Czock verfasserin aut Annette Kopp-Schneider verfasserin aut Reiner Caspari verfasserin aut Harald Fischer verfasserin aut Dana Clarissa Laetsch verfasserin aut Marija Slavic verfasserin aut Hermann Brenner verfasserin aut Ben Schöttker verfasserin aut In Nutrients MDPI AG, 2009 14(2022), 21, p 4546 (DE-627)610604155 (DE-600)2518386-2 20726643 nnns volume:14 year:2022 number:21, p 4546 https://doi.org/10.3390/nu14214546 kostenfrei https://doaj.org/article/835cb6dd73954dfd9d9fb5a75c27dc3d kostenfrei https://www.mdpi.com/2072-6643/14/21/4546 kostenfrei https://doaj.org/toc/2072-6643 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 14 2022 21, p 4546
allfields_unstemmed	10.3390/nu14214546 doi (DE-627)DOAJ086474995 (DE-599)DOAJ835cb6dd73954dfd9d9fb5a75c27dc3d DE-627 ger DE-627 rakwb eng TX341-641 Sabine Kuznia verfasserin aut Efficacy and Safety of a Personalized Vitamin D<sub<3</sub< Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier A personalized vitamin D<sub<3</sub< loading dose has not yet been tested in cancer patients. This interim analysis of the randomized, placebo-controlled VICTORIA trial analyzed the first recruited 74 German adults with nonmetastatic colorectal cancer, a tumor surgery within the past year, and 25-hydroxyvitamin D levels (25(OH)D) < 50 nmol/L. Study participants received a loading dose tailored for a baseline 25(OH)D level and BMI in the first 11 days, followed by a maintenance dose of 2000 IU of vitamin D<sub<3</sub< daily until end of trial week 12. The mean 25(OH)D levels were 27.6, 31.0, and 34.1 nmol/L in the placebo group and 25.9, 63.1, and 75.5 nmol/L in the verum group during screening, visit 1 (end of loading dose), and visit 2 (end of maintenance dose), respectively. The prevalence of 25(OH)D) ≥ 50 nmol/L at visits 1 and 2 was 3.5% and 17.4% in the placebo group and 80.0% and 100% in the verum group. No events of 25(OH)D < 150 nmol/L or hypercalcemia were observed. Hypercalciuria events at visit 1 (<i<n</i< = 5 in verum and <i<n</i< = 1 in the placebo group; <i<p</i< = 0.209) receded after discontinuation of the study medication. The personalized loading dose effectively and safely increased the 25(OH)D levels, and 2000 IU of vitamin D<sub<3</sub< daily sustained the achieved levels. vitamin D colorectal cancer randomized controlled trial personalized medicine loading dose bolus Nutrition. Foods and food supply David Czock verfasserin aut Annette Kopp-Schneider verfasserin aut Reiner Caspari verfasserin aut Harald Fischer verfasserin aut Dana Clarissa Laetsch verfasserin aut Marija Slavic verfasserin aut Hermann Brenner verfasserin aut Ben Schöttker verfasserin aut In Nutrients MDPI AG, 2009 14(2022), 21, p 4546 (DE-627)610604155 (DE-600)2518386-2 20726643 nnns volume:14 year:2022 number:21, p 4546 https://doi.org/10.3390/nu14214546 kostenfrei https://doaj.org/article/835cb6dd73954dfd9d9fb5a75c27dc3d kostenfrei https://www.mdpi.com/2072-6643/14/21/4546 kostenfrei https://doaj.org/toc/2072-6643 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 14 2022 21, p 4546
allfieldsGer	10.3390/nu14214546 doi (DE-627)DOAJ086474995 (DE-599)DOAJ835cb6dd73954dfd9d9fb5a75c27dc3d DE-627 ger DE-627 rakwb eng TX341-641 Sabine Kuznia verfasserin aut Efficacy and Safety of a Personalized Vitamin D<sub<3</sub< Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier A personalized vitamin D<sub<3</sub< loading dose has not yet been tested in cancer patients. This interim analysis of the randomized, placebo-controlled VICTORIA trial analyzed the first recruited 74 German adults with nonmetastatic colorectal cancer, a tumor surgery within the past year, and 25-hydroxyvitamin D levels (25(OH)D) < 50 nmol/L. Study participants received a loading dose tailored for a baseline 25(OH)D level and BMI in the first 11 days, followed by a maintenance dose of 2000 IU of vitamin D<sub<3</sub< daily until end of trial week 12. The mean 25(OH)D levels were 27.6, 31.0, and 34.1 nmol/L in the placebo group and 25.9, 63.1, and 75.5 nmol/L in the verum group during screening, visit 1 (end of loading dose), and visit 2 (end of maintenance dose), respectively. The prevalence of 25(OH)D) ≥ 50 nmol/L at visits 1 and 2 was 3.5% and 17.4% in the placebo group and 80.0% and 100% in the verum group. No events of 25(OH)D < 150 nmol/L or hypercalcemia were observed. Hypercalciuria events at visit 1 (<i<n</i< = 5 in verum and <i<n</i< = 1 in the placebo group; <i<p</i< = 0.209) receded after discontinuation of the study medication. The personalized loading dose effectively and safely increased the 25(OH)D levels, and 2000 IU of vitamin D<sub<3</sub< daily sustained the achieved levels. vitamin D colorectal cancer randomized controlled trial personalized medicine loading dose bolus Nutrition. Foods and food supply David Czock verfasserin aut Annette Kopp-Schneider verfasserin aut Reiner Caspari verfasserin aut Harald Fischer verfasserin aut Dana Clarissa Laetsch verfasserin aut Marija Slavic verfasserin aut Hermann Brenner verfasserin aut Ben Schöttker verfasserin aut In Nutrients MDPI AG, 2009 14(2022), 21, p 4546 (DE-627)610604155 (DE-600)2518386-2 20726643 nnns volume:14 year:2022 number:21, p 4546 https://doi.org/10.3390/nu14214546 kostenfrei https://doaj.org/article/835cb6dd73954dfd9d9fb5a75c27dc3d kostenfrei https://www.mdpi.com/2072-6643/14/21/4546 kostenfrei https://doaj.org/toc/2072-6643 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 14 2022 21, p 4546
allfieldsSound	10.3390/nu14214546 doi (DE-627)DOAJ086474995 (DE-599)DOAJ835cb6dd73954dfd9d9fb5a75c27dc3d DE-627 ger DE-627 rakwb eng TX341-641 Sabine Kuznia verfasserin aut Efficacy and Safety of a Personalized Vitamin D<sub<3</sub< Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier A personalized vitamin D<sub<3</sub< loading dose has not yet been tested in cancer patients. This interim analysis of the randomized, placebo-controlled VICTORIA trial analyzed the first recruited 74 German adults with nonmetastatic colorectal cancer, a tumor surgery within the past year, and 25-hydroxyvitamin D levels (25(OH)D) < 50 nmol/L. Study participants received a loading dose tailored for a baseline 25(OH)D level and BMI in the first 11 days, followed by a maintenance dose of 2000 IU of vitamin D<sub<3</sub< daily until end of trial week 12. The mean 25(OH)D levels were 27.6, 31.0, and 34.1 nmol/L in the placebo group and 25.9, 63.1, and 75.5 nmol/L in the verum group during screening, visit 1 (end of loading dose), and visit 2 (end of maintenance dose), respectively. The prevalence of 25(OH)D) ≥ 50 nmol/L at visits 1 and 2 was 3.5% and 17.4% in the placebo group and 80.0% and 100% in the verum group. No events of 25(OH)D < 150 nmol/L or hypercalcemia were observed. Hypercalciuria events at visit 1 (<i<n</i< = 5 in verum and <i<n</i< = 1 in the placebo group; <i<p</i< = 0.209) receded after discontinuation of the study medication. The personalized loading dose effectively and safely increased the 25(OH)D levels, and 2000 IU of vitamin D<sub<3</sub< daily sustained the achieved levels. vitamin D colorectal cancer randomized controlled trial personalized medicine loading dose bolus Nutrition. Foods and food supply David Czock verfasserin aut Annette Kopp-Schneider verfasserin aut Reiner Caspari verfasserin aut Harald Fischer verfasserin aut Dana Clarissa Laetsch verfasserin aut Marija Slavic verfasserin aut Hermann Brenner verfasserin aut Ben Schöttker verfasserin aut In Nutrients MDPI AG, 2009 14(2022), 21, p 4546 (DE-627)610604155 (DE-600)2518386-2 20726643 nnns volume:14 year:2022 number:21, p 4546 https://doi.org/10.3390/nu14214546 kostenfrei https://doaj.org/article/835cb6dd73954dfd9d9fb5a75c27dc3d kostenfrei https://www.mdpi.com/2072-6643/14/21/4546 kostenfrei https://doaj.org/toc/2072-6643 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 14 2022 21, p 4546
language	English
source	In Nutrients 14(2022), 21, p 4546 volume:14 year:2022 number:21, p 4546
sourceStr	In Nutrients 14(2022), 21, p 4546 volume:14 year:2022 number:21, p 4546
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	vitamin D colorectal cancer randomized controlled trial personalized medicine loading dose bolus Nutrition. Foods and food supply
isfreeaccess_bool	true
container_title	Nutrients
authorswithroles_txt_mv	Sabine Kuznia @@aut@@ David Czock @@aut@@ Annette Kopp-Schneider @@aut@@ Reiner Caspari @@aut@@ Harald Fischer @@aut@@ Dana Clarissa Laetsch @@aut@@ Marija Slavic @@aut@@ Hermann Brenner @@aut@@ Ben Schöttker @@aut@@
publishDateDaySort_date	2022-01-01T00:00:00Z
hierarchy_top_id	610604155
id	DOAJ086474995
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ086474995</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414171533.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/nu14214546</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ086474995</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ835cb6dd73954dfd9d9fb5a75c27dc3d</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">TX341-641</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Sabine Kuznia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Efficacy and Safety of a Personalized Vitamin D<sub<3</sub< Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">A personalized vitamin D<sub<3</sub< loading dose has not yet been tested in cancer patients. This interim analysis of the randomized, placebo-controlled VICTORIA trial analyzed the first recruited 74 German adults with nonmetastatic colorectal cancer, a tumor surgery within the past year, and 25-hydroxyvitamin D levels (25(OH)D) < 50 nmol/L. Study participants received a loading dose tailored for a baseline 25(OH)D level and BMI in the first 11 days, followed by a maintenance dose of 2000 IU of vitamin D<sub<3</sub< daily until end of trial week 12. The mean 25(OH)D levels were 27.6, 31.0, and 34.1 nmol/L in the placebo group and 25.9, 63.1, and 75.5 nmol/L in the verum group during screening, visit 1 (end of loading dose), and visit 2 (end of maintenance dose), respectively. The prevalence of 25(OH)D) ≥ 50 nmol/L at visits 1 and 2 was 3.5% and 17.4% in the placebo group and 80.0% and 100% in the verum group. No events of 25(OH)D < 150 nmol/L or hypercalcemia were observed. Hypercalciuria events at visit 1 (<i<n</i< = 5 in verum and <i<n</i< = 1 in the placebo group; <i<p</i< = 0.209) receded after discontinuation of the study medication. The personalized loading dose effectively and safely increased the 25(OH)D levels, and 2000 IU of vitamin D<sub<3</sub< daily sustained the achieved levels.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">vitamin D</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">colorectal cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">randomized controlled trial</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">personalized medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">loading dose</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">bolus</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Nutrition. Foods and food supply</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">David Czock</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Annette Kopp-Schneider</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Reiner Caspari</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Harald Fischer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dana Clarissa Laetsch</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marija Slavic</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hermann Brenner</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ben Schöttker</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Nutrients</subfield><subfield code="d">MDPI AG, 2009</subfield><subfield code="g">14(2022), 21, p 4546</subfield><subfield code="w">(DE-627)610604155</subfield><subfield code="w">(DE-600)2518386-2</subfield><subfield code="x">20726643</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:14</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:21, p 4546</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/nu14214546</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/835cb6dd73954dfd9d9fb5a75c27dc3d</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2072-6643/14/21/4546</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-6643</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">14</subfield><subfield code="j">2022</subfield><subfield code="e">21, p 4546</subfield></datafield></record></collection>
callnumber-first	T - Technology
author	Sabine Kuznia
spellingShingle	Sabine Kuznia misc TX341-641 misc vitamin D misc colorectal cancer misc randomized controlled trial misc personalized medicine misc loading dose misc bolus misc Nutrition. Foods and food supply Efficacy and Safety of a Personalized Vitamin D<sub<3</sub< Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial
authorStr	Sabine Kuznia
ppnlink_with_tag_str_mv	@@773@@(DE-627)610604155
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	TX341-641
illustrated	Not Illustrated
issn	20726643
topic_title	TX341-641 Efficacy and Safety of a Personalized Vitamin D<sub<3</sub< Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial vitamin D colorectal cancer randomized controlled trial personalized medicine loading dose bolus
topic	misc TX341-641 misc vitamin D misc colorectal cancer misc randomized controlled trial misc personalized medicine misc loading dose misc bolus misc Nutrition. Foods and food supply
topic_unstemmed	misc TX341-641 misc vitamin D misc colorectal cancer misc randomized controlled trial misc personalized medicine misc loading dose misc bolus misc Nutrition. Foods and food supply
topic_browse	misc TX341-641 misc vitamin D misc colorectal cancer misc randomized controlled trial misc personalized medicine misc loading dose misc bolus misc Nutrition. Foods and food supply
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Nutrients
hierarchy_parent_id	610604155
hierarchy_top_title	Nutrients
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)610604155 (DE-600)2518386-2
title	Efficacy and Safety of a Personalized Vitamin D<sub<3</sub< Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial
ctrlnum	(DE-627)DOAJ086474995 (DE-599)DOAJ835cb6dd73954dfd9d9fb5a75c27dc3d
title_full	Efficacy and Safety of a Personalized Vitamin D<sub<3</sub< Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial
author_sort	Sabine Kuznia
journal	Nutrients
journalStr	Nutrients
callnumber-first-code	T
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2022
contenttype_str_mv	txt
author_browse	Sabine Kuznia David Czock Annette Kopp-Schneider Reiner Caspari Harald Fischer Dana Clarissa Laetsch Marija Slavic Hermann Brenner Ben Schöttker
container_volume	14
class	TX341-641
format_se	Elektronische Aufsätze
author-letter	Sabine Kuznia
doi_str_mv	10.3390/nu14214546
author2-role	verfasserin
title_sort	efficacy and safety of a personalized vitamin d<sub<3</sub< loading dose followed by daily 2000 iu in colorectal cancer patients with vitamin d insufficiency: interim analysis of a randomized controlled trial
callnumber	TX341-641
title_auth	Efficacy and Safety of a Personalized Vitamin D<sub<3</sub< Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial
abstract	A personalized vitamin D<sub<3</sub< loading dose has not yet been tested in cancer patients. This interim analysis of the randomized, placebo-controlled VICTORIA trial analyzed the first recruited 74 German adults with nonmetastatic colorectal cancer, a tumor surgery within the past year, and 25-hydroxyvitamin D levels (25(OH)D) < 50 nmol/L. Study participants received a loading dose tailored for a baseline 25(OH)D level and BMI in the first 11 days, followed by a maintenance dose of 2000 IU of vitamin D<sub<3</sub< daily until end of trial week 12. The mean 25(OH)D levels were 27.6, 31.0, and 34.1 nmol/L in the placebo group and 25.9, 63.1, and 75.5 nmol/L in the verum group during screening, visit 1 (end of loading dose), and visit 2 (end of maintenance dose), respectively. The prevalence of 25(OH)D) ≥ 50 nmol/L at visits 1 and 2 was 3.5% and 17.4% in the placebo group and 80.0% and 100% in the verum group. No events of 25(OH)D < 150 nmol/L or hypercalcemia were observed. Hypercalciuria events at visit 1 (<i<n</i< = 5 in verum and <i<n</i< = 1 in the placebo group; <i<p</i< = 0.209) receded after discontinuation of the study medication. The personalized loading dose effectively and safely increased the 25(OH)D levels, and 2000 IU of vitamin D<sub<3</sub< daily sustained the achieved levels.
abstractGer	A personalized vitamin D<sub<3</sub< loading dose has not yet been tested in cancer patients. This interim analysis of the randomized, placebo-controlled VICTORIA trial analyzed the first recruited 74 German adults with nonmetastatic colorectal cancer, a tumor surgery within the past year, and 25-hydroxyvitamin D levels (25(OH)D) < 50 nmol/L. Study participants received a loading dose tailored for a baseline 25(OH)D level and BMI in the first 11 days, followed by a maintenance dose of 2000 IU of vitamin D<sub<3</sub< daily until end of trial week 12. The mean 25(OH)D levels were 27.6, 31.0, and 34.1 nmol/L in the placebo group and 25.9, 63.1, and 75.5 nmol/L in the verum group during screening, visit 1 (end of loading dose), and visit 2 (end of maintenance dose), respectively. The prevalence of 25(OH)D) ≥ 50 nmol/L at visits 1 and 2 was 3.5% and 17.4% in the placebo group and 80.0% and 100% in the verum group. No events of 25(OH)D < 150 nmol/L or hypercalcemia were observed. Hypercalciuria events at visit 1 (<i<n</i< = 5 in verum and <i<n</i< = 1 in the placebo group; <i<p</i< = 0.209) receded after discontinuation of the study medication. The personalized loading dose effectively and safely increased the 25(OH)D levels, and 2000 IU of vitamin D<sub<3</sub< daily sustained the achieved levels.
abstract_unstemmed	A personalized vitamin D<sub<3</sub< loading dose has not yet been tested in cancer patients. This interim analysis of the randomized, placebo-controlled VICTORIA trial analyzed the first recruited 74 German adults with nonmetastatic colorectal cancer, a tumor surgery within the past year, and 25-hydroxyvitamin D levels (25(OH)D) < 50 nmol/L. Study participants received a loading dose tailored for a baseline 25(OH)D level and BMI in the first 11 days, followed by a maintenance dose of 2000 IU of vitamin D<sub<3</sub< daily until end of trial week 12. The mean 25(OH)D levels were 27.6, 31.0, and 34.1 nmol/L in the placebo group and 25.9, 63.1, and 75.5 nmol/L in the verum group during screening, visit 1 (end of loading dose), and visit 2 (end of maintenance dose), respectively. The prevalence of 25(OH)D) ≥ 50 nmol/L at visits 1 and 2 was 3.5% and 17.4% in the placebo group and 80.0% and 100% in the verum group. No events of 25(OH)D < 150 nmol/L or hypercalcemia were observed. Hypercalciuria events at visit 1 (<i<n</i< = 5 in verum and <i<n</i< = 1 in the placebo group; <i<p</i< = 0.209) receded after discontinuation of the study medication. The personalized loading dose effectively and safely increased the 25(OH)D levels, and 2000 IU of vitamin D<sub<3</sub< daily sustained the achieved levels.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	21, p 4546
title_short	Efficacy and Safety of a Personalized Vitamin D<sub<3</sub< Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial
url	https://doi.org/10.3390/nu14214546 https://doaj.org/article/835cb6dd73954dfd9d9fb5a75c27dc3d https://www.mdpi.com/2072-6643/14/21/4546 https://doaj.org/toc/2072-6643
remote_bool	true
author2	David Czock Annette Kopp-Schneider Reiner Caspari Harald Fischer Dana Clarissa Laetsch Marija Slavic Hermann Brenner Ben Schöttker
author2Str	David Czock Annette Kopp-Schneider Reiner Caspari Harald Fischer Dana Clarissa Laetsch Marija Slavic Hermann Brenner Ben Schöttker
ppnlink	610604155
callnumber-subject	TX - Home Economics
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/nu14214546
callnumber-a	TX341-641
up_date	2024-07-03T20:54:49.338Z
_version_	1803592756719779840
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ086474995</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414171533.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/nu14214546</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ086474995</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ835cb6dd73954dfd9d9fb5a75c27dc3d</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">TX341-641</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Sabine Kuznia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Efficacy and Safety of a Personalized Vitamin D<sub<3</sub< Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">A personalized vitamin D<sub<3</sub< loading dose has not yet been tested in cancer patients. This interim analysis of the randomized, placebo-controlled VICTORIA trial analyzed the first recruited 74 German adults with nonmetastatic colorectal cancer, a tumor surgery within the past year, and 25-hydroxyvitamin D levels (25(OH)D) < 50 nmol/L. Study participants received a loading dose tailored for a baseline 25(OH)D level and BMI in the first 11 days, followed by a maintenance dose of 2000 IU of vitamin D<sub<3</sub< daily until end of trial week 12. The mean 25(OH)D levels were 27.6, 31.0, and 34.1 nmol/L in the placebo group and 25.9, 63.1, and 75.5 nmol/L in the verum group during screening, visit 1 (end of loading dose), and visit 2 (end of maintenance dose), respectively. The prevalence of 25(OH)D) ≥ 50 nmol/L at visits 1 and 2 was 3.5% and 17.4% in the placebo group and 80.0% and 100% in the verum group. No events of 25(OH)D < 150 nmol/L or hypercalcemia were observed. Hypercalciuria events at visit 1 (<i<n</i< = 5 in verum and <i<n</i< = 1 in the placebo group; <i<p</i< = 0.209) receded after discontinuation of the study medication. The personalized loading dose effectively and safely increased the 25(OH)D levels, and 2000 IU of vitamin D<sub<3</sub< daily sustained the achieved levels.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">vitamin D</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">colorectal cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">randomized controlled trial</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">personalized medicine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">loading dose</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">bolus</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Nutrition. Foods and food supply</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">David Czock</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Annette Kopp-Schneider</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Reiner Caspari</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Harald Fischer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dana Clarissa Laetsch</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marija Slavic</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hermann Brenner</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ben Schöttker</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Nutrients</subfield><subfield code="d">MDPI AG, 2009</subfield><subfield code="g">14(2022), 21, p 4546</subfield><subfield code="w">(DE-627)610604155</subfield><subfield code="w">(DE-600)2518386-2</subfield><subfield code="x">20726643</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:14</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:21, p 4546</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/nu14214546</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/835cb6dd73954dfd9d9fb5a75c27dc3d</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2072-6643/14/21/4546</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2072-6643</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">14</subfield><subfield code="j">2022</subfield><subfield code="e">21, p 4546</subfield></datafield></record></collection>
score	7.399441

Nicht das Richtige dabei?

Schreiben Sie uns!

Efficacy and Safety of a Personalized Vitamin D<sub<3</sub< Loading Dose Followed by Daily 2000 IU in Colorectal Cancer Patients with Vitamin D Insufficiency: Interim Analysis of a Randomized Controlled Trial

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?